<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556244</url>
  </required_header>
  <id_info>
    <org_study_id>200704053M</org_study_id>
    <nct_id>NCT00556244</nct_id>
  </id_info>
  <brief_title>Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling</brief_title>
  <official_title>Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Internal limiting membrane peeling in diabetic vitrectomy will help prevent postoperative&#xD;
      epiretinal membrane formation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progressive fibrovascular proliferation may occur despite appropriate panretinal&#xD;
      photocoagulation in diabetic patients. Fibrovascular proliferation may lead to persistent or&#xD;
      recurrent vitreous hemorrhage, macular traction, or traction macular detachment, and becomes&#xD;
      a major indication for vitrectomy.1 During the past 25 years, anatomical and visual results&#xD;
      of vitrectomy for severe proliferative diabetic retinopathy have improved as a result of&#xD;
      improved understanding of the pathoanatomy and improvements in surgical instrumentation.2-5&#xD;
      Although anatomical success is high after complete vitrectomy, recurrent epiretinal membrane&#xD;
      may cause macular thickening, cysts formation, preventing good functional outcome.6 An&#xD;
      epiretinal membrane (ERM) is a non-vascular cellular membrane that may cause symptomatic&#xD;
      visual disturbances due to retinal wrinkling and distortion.7 These epiretinal membranes have&#xD;
      been found to be composed of fibroblasts, glial cells, macrophages, myofiboblasts, nad&#xD;
      retinal pigment epithelial cells.8-9 Studies have suggested removal of internal limiting&#xD;
      membrane (ILM) may decrease the likelihood of post-operative ERM formation in cases of&#xD;
      diabetic macular edema and idiopathic ERM. It is postulated that removal of the ILM removes&#xD;
      the scaffold upon which myofibroblasts would proliferate.10 Efficacy of vitrectomy including&#xD;
      removal of ILM was mostly described as facilitating resolution of diffuse diabetic macular&#xD;
      edema11 and improvement of visual acuity or in macular hole surgery in diabetic&#xD;
      patients.12However, it is unknown if removal of ILM during vitreoretinal surgery in diabetic&#xD;
      patients with active fibrovascular proliferation is useful in preventing postoperative ERM&#xD;
      formation. The purpose of this study is to compare the postoperative epiretinal membrane&#xD;
      (ERM) formation and visual outcome in diabetic patients with active fibrovascular&#xD;
      proliferation who underwent vitrectomy with or without ILM peeling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">November 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Snellen BCVA and epiretinal membrane formation measured with OCT</measure>
    <time_frame>within 6 months after the surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>central macular thickness measured bt OCT</measure>
    <time_frame>within 6 months after the surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Patients With Proliferative Diabetic Retinopathy Who Have Active Fibrovascular Proliferation</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ILM peeling</intervention_name>
    <description>ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  active fibrovascular proliferation with or without tractional detachment&#xD;
&#xD;
          -  previous pan-retinal photocoagulation at least 3 months before&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  biomicroscopic evidence of macular hole&#xD;
&#xD;
          -  combination of tractional and rhegmatogenous retinal detachment&#xD;
&#xD;
          -  location of fibrovascular proliferation anterior to the equator&#xD;
&#xD;
          -  major ocular surgery history(including, scleral buckle, glaucoma filter, cornea&#xD;
             transplant, vitreoretinal surgery etc&#xD;
&#xD;
          -  the presence of other ocular conditions such as glaucoma, uveitis, or other ocular&#xD;
             inflammatory diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung-may Yang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei-yao Chang, M.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>5187</phone_ext>
    <email>peiyao@seed.net.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-may Yang, M.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>5187</phone_ext>
      <email>peiyao@seed.net.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <last_update_submitted>November 8, 2007</last_update_submitted>
  <last_update_submitted_qc>November 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

